Title

LIP-01 in Hypercholesterolemia
An Open-label Dose-finding Study of LIP-01 in Otherwise Healthy Individuals With Hypercholesterolemia
  • Phase

    Phase 1
  • Study Type

    Interventional
  • Status

    Completed No Results Posted
  • Study Participants

    40
The purpose of this study is to determine a safe and tolerable dose of LIP-01
Study Started
Sep 30
2009
Primary Completion
Jan 31
2012
Study Completion
Jan 31
2012
Last Update
Jan 31
2012
Estimate

Dietary Supplement LIP-01

comparison of different dosages of natural health product

One gram LIP-01 per day Experimental

One gram LIP-01 per day for 12 weeks

Two grams LIP-01 per day Experimental

Two grams LIP-01 per day for 12 weeks

0.333 grams LIP-01 per day Experimental

0.333 grams LIP-01 per day for 12 weeks

Criteria

Inclusion Criteria:

Age between 18-75 years
Plasma total-cholesterol >5.2 mmol/L (> 200 mg/dL)
Willingness to adhere to the requirements of the protocol, including availability for follow-up visits and donation of blood samples
Willingness and ability to sign written informed consent
Women of child bearing capacity who agree to use an acceptable form of birth control during the trial [i.e., oral contraception, reliable use of a double-barrier method (e.g., condom and diaphragm, condom and foam, condom and sponge), IUD or tubal ligation]

Exclusion Criteria:

Plasma triglycerides > 4.0 mmol/L (> 354 mg/dL)
Plasma LDL ≥ 5.0 mmol/L (≥ 195 mg/dL)
Current coronary artery/ cardiovascular disease or history of a cardiovascular event (stroke, transient ischemic attack, myocardial infarction, angioplasty or coronary artery bypass grafting, angina pectoris)
Moderate/high risk of coronary artery/ cardiovascular disease
Diabetes mellitus
Uncorrected hypothyroidism
Other significant metabolic endocrine disease
Uncontrolled hypertension (>160 systolic or >100 diastolic)
Active liver disease (ALT >2x normal)
Significant gastrointestinal disease
Acute inflammatory disease
Significant kidney disease (calculated by eGFR <60 mL/min)
Any other significant medical condition which, in the opinion of the investigator, could compromise patient safety or confound trial results
Any significant/relevant surgery within the last year
Use of lipid-lowering drugs
Treatment within the previous 6 months with any medication that is known to affect lipid or lipoprotein levels (such as statins, fibric acid derivatives, bile acid sequestrants, ezetimibe, nicotinic acid)
Regular use of natural health products or dietary supplements known to affect lipid or lipoprotein levels (omega-3 fatty acids, green tea extracts, guggulipid, psyllium, plant sterols, policosanols). If the participants agree to stop taking these products prior to study entry and for the duration of the study, they can participate in the study.
Pregnant or lactating women
Known allergy to any ingredient in the study product, including: Coptis chinensis, Ilex kudingcha, microcrystalline cellulose and magnesium stearate
No Results Posted